BioSpace News Archive

Durable Clinical Benefits Induced by IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting

PD-L1 positive subjects demonstrated Objective Response Rate (ORR) of 86 % associated with long duration of clinical benefits

December 6, 2020
·
8 min read
Biotech Bay

Corvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Annual Meeting & Exposition

Updated interimdata from CPI-818’sphase 1/1b clinical trial provide evidence supporting its potential as a treatment for T cell lymphomas

December 6, 2020
·
10 min read
Biotech Bay

GBT Presents Data on New Sickle Cell Disease Pipeline Therapies with Best-in-Class Potential – Inclacumab and GBT021601

GBT021601 – Potent Next-Generation Hemoglobin S Polymerization Inhibitor Shown to be Highly Effective in SCD Animal Models

December 6, 2020
·
14 min read
BioCapital

CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma

ACE-LY-004 Phase II trial results substantiate established efficacy and safety profile of CALQUENCE in mantle cell lymphoma

December 6, 2020
·
16 min read
Drug Development

Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD

Data featured during oral session at the 62nd ASH Annual Meeting demonstrate deep, durable responses and multiorgan clinical benefit in patients refractory to multiple therapeutic agents

December 6, 2020
·
8 min read
BioForest

CTI BioPharma Announces Presentation of Data Supporting Pacritinib’s Potential Benefit in Preventing Acute GVHD at the 62nd American Society of Hematology Meeting

Results from Investigator-sponsored Phase 1/2 Study of Acute GVHD Prophylaxis Following Allogeneic Hematopoietic Cell Transplantation Demonstrate Encouraging Efficacy and Safety Profile when Combining Pacritinib 100 mg BID with Standard Immunosuppressive Therapy

December 6, 2020
·
6 min read
Biotech Bay

GBT Presents New Data on the Long-Term and Real-World Use of Oxbryta® (voxelotor) Tablets in Patients with Sickle Cell Disease at 62nd ASH Annual Meeting and Exposition

Final 72-Week Analyses of Phase 3 HOPE Study Demonstrate Durable Improvements in Hemoglobin Levels and Significant Improvements in Overall Health Status

December 6, 2020
·
14 min read
Drug Development

Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meeting

Preliminary Data from First Patient Demonstrates Initial Safety and Tolerability of RP-L301, Near Doubling of Hemoglobin to Normal Range and Additional Normalization of Hemolysis Markers

December 6, 2020
·
8 min read
Biotech Bay

First Clinical Data from Ongoing Orca-T Trial Shows Significantly Improved 12-Month Graft Versus Host Disease (GvHD)-Free and Relapse-Free Survival (GRFS) in Blood Cancer Patients Receiving a Hematopoietic Stem Cell Transplant (HSCT)

Early multi-center results indicate that Orca-T, a novel approach to HSCT,improves time-to-engraftment, markedly reducesthe incidence and severity of GvHD, and significantly improved GRFS at 1 year

December 6, 2020
·
3 min read
Drug Development

Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients

Similar Overall and Complete Response Rates Observed Across Frontline AML Patients Ineligible for Intensive Chemotherapy and in High Unmet Need Patients with TP53-Mutant AML

December 6, 2020
·
7 min read